(Q39535188)

12 September 2017

title

Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A85162

11 November 2022

0 references

1 reference

1

Y Agid

1 reference

12 September 2017

P. Pollak

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A85162

11 November 2022

A. M. Bonnet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A85162

11 November 2022

J. L. Signoret

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A85162

11 November 2022

F. Lhermitte

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A85162

11 November 2022

language of work or name

English

0 references

publication date

1 March 1979

1 reference

12 September 2017

17 March 1979

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=85162

full work available at URL

11 November 2022

https://api.elsevier.com/content/article/PII:S0140673679910031?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(79)91003-1

https://api.elsevier.com/content/article/PII:S0140673679910031?httpAccept=text/plain

11 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(79)91003-1

11 November 2022

1 reference

12 September 2017

volume

1

1 reference

12 September 2017

issue

8116

1 reference

12 September 2017

page(s)

570-572

1 reference

Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Comparison of the effects of bromocriptine and levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

The cardiovascular effects of bromocriptine in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Treatment of parkinson's disease with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Idiopathic parkinsonism treated with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Bromocriptine in Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Long-term treatment of parkinsonism with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

1 reference

7 January 2021

Locus of the central emetic action of cardiac glycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2879%2991003-1

7 January 2021

Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa

7

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(79)91003-1

11 November 2022

Identifiers

1 reference

12 September 2017

1 reference